علاج تشريح الشريان السباتي مع خطر نزيف معتدل وخصائص إشعاعية عالية الخطورة

References

• The presence of radiographic high-risk features that are known predictors of ischemic stroke after dissection (such as severe stenosis or occlusion, intraluminal thrombus) in patients with low risk of bleeding may warrant anticoagulation therapy.
• Although the evidence for use in cervical artery dissection is weak, a short course of dual antiplatelet therapy with a loading dose (followed by single antiplatelet agent) might be preferred over monotherapy when deemed safe, particularly in patients who would have qualified for the dual antiplatelet trials for early prevention after minor stroke/TIA.
• Patients without radiographic high-risk features or those with an elevated risk of extracranial hemorrhage or ICH (eg, large infarct size, hemorrhagic transformation, intradural extension of extracranial dissection) may be better suited for antiplatelet therapy, with either antiplatelet monotherapy or a short course of dual antiplatelet therapy for 21 to 90 days (in line with minor stroke/TIA and CADISS) if considered safe, followed by single antiplatelet therapy.
• It is reasonable that the duration of antithrombotic therapy in patients with cervical artery dissection be 3–6 mo.